Search for: "Frank L. Martin" Results 201 - 220 of 227
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
5 Dec 2008, 9:11 pm
Gibbons added new IP partners Frank Bruno, from Milbank, Tweed, Hadley & McCloy, and Nancy Mertzel, from Thelen. [read post]
2 Oct 2008, 9:51 am
PANEL 2A – La formation contrat électronique Vendredi 3 octobre 2008 AM PRÉSIDENT : Stefan MARTIN (Avocat - Fraser Milner Casgrain) Convention de la CNUDCI (2005) - John GREGORY (Avocat – Gouvernement de l’Ontario) La formation du contrat au Canada - Marc A. [read post]
2 Oct 2008, 9:51 am
PANEL 2A – La formation contrat électronique Vendredi 3 octobre 2008 AM PRÉSIDENT : Stefan MARTIN (Avocat - Fraser Milner Casgrain) Convention de la CNUDCI (2005) - John GREGORY (Avocat – Gouvernement de l’Ontario) La formation du contrat au Canada - Marc A. [read post]
2 Oct 2008, 9:51 am
PANEL 2A – La formation contrat électronique Vendredi 3 octobre 2008 AM PRÉSIDENT : Stefan MARTIN (Avocat - Fraser Milner Casgrain) Convention de la CNUDCI (2005) - John GREGORY (Avocat – Gouvernement de l’Ontario) La formation du contrat au Canada - Marc A. [read post]
12 Aug 2008, 2:00 pm
Environmental 3 Anurag Parkash VP Real Estate Property Management 2 Anurag Parkash VP Real Estate Property Management 2 Jacob klein J.KLEIN ASSOCIATES realty insurance brokerage 2 Howard Schwartz Diamond Vault International Self Employed 3 Annie Yao Newmark Knight Frank Commercial Leasing 2 vinod gadura gadurarealestate Brokerage - commerciall 3 Alice P. [read post]
18 Apr 2008, 2:00 am
Lélos Kai Sia EE (and Others) v GlaxoSmithKline AEVE: (IPKat), US: Bio commends Sen Specter for patent reform stance: (Patent Docs), US: USPTO rules on two of four neural stem cell patents in dispute between StemCells Inc and Neuralstem Inc; parties disagree on how extensively claims amended: (IP Law360), (IPBiz), US: Insmed continues fight for generic biologic approval: (GenericsWeb), Pharma & Biotech - Products Cipralex (Escitalopram) –… [read post]
14 Apr 2008, 9:02 am
Martin for awarding "egregious" pay packages to top executives, and ignoring shareholder disapproval on the issue. [read post]